Health Gene Technologies Raises 220 Million Yuan

Health Gene Technologies announced the completion of a round A financing of 220 million yuan. The financing was led by Qiming Venture Capital, followed by GL Capital Group, BioTrack Capital, and Prosperico Ventures.

Funds from this round of financing will be mainly used for the exploration of new technologies by HGT, R&D investment in new product development, and team and business development.

Ningbo Health Gene Technologies Co., Ltd (HGT) is a wholly-owned subsidiary of Health BioMed Co., Ltd (HBM). HGT, found in 2011, has dedicated its business to gene fragment analysis application development. HGT has a 2000 m2 molecular diagnostic R&D laboratory and a 1000 m2  reagent production plant, in accordance with GMP.

Equipped with state-of-the-art research and production facilities, HGT is committed to developing simple, rapid and effective nucleic acid testing solutions for molecular diagnostics, clinical research and forensic analysis. Inspired by our motto 'Health Technologies•Healthy Life', HGT cares not only about the products but also about environmental protection. HGT follows a comprehensive sustainability policy making the processes of research and manufacturing more environmentally friendly.

In the field of forensic science, Haier Gene Technology has become one of the largest suppliers of forensic DNA testing reagents in China. In 2020, a unique solid spherical forensic DNA case detection reagent will be launched, leading the industry technology development trend.

In addition, HGT aims to help people achieve a better quality life by the development of its healthcare solutions. It dedicates to develop and manufacture Advanced Fragment Analysis (AFA) based in vitro diagnostic kits for many different applications, such as PathogenDetection, Pharmacogenomics Analysis and Human DNA Identification.